Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value

Leukemia

Volumn 28, Issue 9, 2014, Pages 1811-1818

  Vannucchi, A M ^a,b   Rotunno, G ^a,b   Bartalucci, N ^a,b   Raugei, G ^b   Carrai, V ^b   Balliu, M ^a   Mannarelli, C ^a,b   Pacilli, A ^a,b   Calabresi, L ^a,b   Fjerza, R ^a,b   Pieri, L ^a,b   Bosi, A ^a,b   Manfredini, R ^c   Guglielmelli, P ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; POLYCLONAL ANTIBODY;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; ERYTHROID CELL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MEGAKARYOCYTE; MYELOID METAPLASIA; PRIORITY JOURNAL; THROMBOCYTHEMIA; WESTERN BLOTTING;

CALRETICULIN; CELL LINEAGE; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, THROMBOPOIETIN;

EID: 84908308927     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.100     Document Type: Article

References (36)

1. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V., et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005; 19: 1847-1849
2. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366: 1945-1953
3. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ., et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-Term prognostic relevance. Br J Haematol. 2005; 131: 208-213
4. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY., et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005; 131: 320-328
5. Barosi G, Bergamaschi G,Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007; 110: 4030-4036
6. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY., et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008; 22: 756-761
7. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of. 1182 patients. Blood. 2006; 108: 3472-3476
8. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E., et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007; 137: 244-247
9. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3: e270
10. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007; 110: 1092-1097
11. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H., et al. (eds) WHO classification of Tumors of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, 2008
12. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC., et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013; 369: 2391-2405
13. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379-2390
14. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014; 28: 1407-1413
15. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013; 27: 1953-1958
16. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD., et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2013; e-pub ahead of print 23 December 2013
17. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V., et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007; 21: 1952-1959
18. Pancrazzi A, Guglielmelli P, Ponziani V, Bergamaschi G, Bosi A, Barosi G., et al. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-Time polymerase chain reaction. J Mol Diagn. 2008; 10: 435-441
19. Rumi E, Pietra D, Guglielmelli P, Bordoni R, Casetti I, Milanesi C., et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013; 121: 4388-4395
20. Manfredini R, Zini R, Salati S, Siena M, Tenedini E, Tagliafico E., et al. The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment. Stem Cells. 2005; 23: 496-506
21. Tenedini E, Fagioli ME, Vianelli N, Tazzari PL, Ricci F, Tagliafico E., et al. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood. 2004; 104: 3126-3135
22. Grande A, Piovani B, Aiuti A, Ottolenghi S, Mavilio F, Ferrari G. Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells. Blood. 1999; 93: 3276-3285
23. Gemelli C, Montanari M, Tenedini E, Zanocco Marani T, Vignudelli T, Siena M., et al. Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell DeathDiffer. 2006; 13: 1686-1696
24. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4: 249-264
25. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH., et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014; 28: 1472-1477
26. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014; e-pub ahead of print 29 January 2014
27. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008; 22: 1841-1848
28. Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008; 111: 3863-3866
29. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG., et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol. 2006; 135: 683-687
30. Hou H-A, Kuo Y-Y, Chou W-C, Chen P-H, Tien H-F. Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome. Leukemia. 2014; 28: 1555-1557
31. Broséus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L., et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014; 28: 1374-1376
32. Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol. 2014; e-pub ahead of print 13 January. 2014; doi:10.1002/ajh.23665
33. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B., et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-Associated myeloproliferative neoplasms: a joint European LeukemiaNet/.MPN&Nr-EuroNet (COST action BM0902) study. Leukemia. 2013; 27: 2032-2039
34. Elton CM, Smethurst PA, Eggleton P, Farndale RW. Physical and functional interaction between cell-surface calreticulin and the collagen receptors integrin alpha2beta1 and glycoprotein VI in human platelets. Thromb Haemost. 2002; 88: 648-654
35. Ghebrehiwet B, Peerschke EI. cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection. Mol Immunol. 2004; 41: 173-183
36. Clark RA, Li SL, Pearson DW, Leidal KG, Clark JR, Denning GM., et al. Regulation of calreticulin expression during induction of differentiation in human myeloid cells. Evidence for remodeling of the endoplasmic reticulum. J Biol Chem. 2002; 277: 32369-32378